Personalized Cellular Vaccine for Glioblastoma (PERCELLVAC)

Glioblastoma Clinical Trial

— PERCELLVAC  

Official title:

Personalized Cellular Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma (PerCellVac)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02709616
• Other study ID #: Ag-mRNA-DC-999brain
• Status: Completed
• Phase: Phase 1
• Start date: March 1, 2016
• Est. completion date: June 30, 2019

Study information

• Verified date: May 2022
• Source: Guangdong 999 Brain Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Dendritic cell-based cellular vaccine for tumor therapy has shown efficacy. This study is designed to perform a personalized clinical trial by first analyzing the expression of tumor associated antigens in patients with newly diagnosed glioblastoma and then immunizing the patients with personalized DC-based cellular vaccine. Immune responses to tumor antigens will be monitored. Safety and efficacy will be observed in the study.

Description:

This is an open label, single-arm, single-institution, Phase I study designed to investigate the safety and efficacy of personalized cellular tumor vaccine for patients with newly diagnosed glioblastoma (GBM). Newly diagnosed GBM patients will undergo tumor resection. The tumors will be analyzed for the expression of a panel of glioma-associated antigens and immune-related genes. Post surgical treatment will be 6 weeks standard chemotherapy with temozolomide and concurrent radiotherapy and continue cycles of temozolomide within a 28-day window. Patients will undergo leukapheresis either after surgery or after concurrent radio/chemotherapy. Based on individual tumor antigen expression, in vitro transcribed mRNA will be generated and used to pulse in vitro generated DCs. The patients will be immunized i.d. and i.v. biweekly with DC cellular vaccines. Safety and efficacy will be monitored. The primary objective is to assess the safety of the personalized cellular vaccines. The secondary objective is to assess the specific T cell response to immunized vaccines. In addition, the antitumor efficacy of the vaccines will be measured using iRANO criteria, progression-free survival and overall survival.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: June 30, 2019
• Est. primary completion date: October 31, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Newly diagnosed glioblastoma grade IV

• Patients at the age of 18-65.

• Patients must have undergone maximal surgical resection of the tumor.

• Patients with Karnofsky scores > or =70

• Patients with normal range of hematologic and metabolic test results.

• Patients must have no corticosteroids treatment at least one week before vaccination.

• Patients capable of understanding the study and signed informed consent.

Exclusion Criteria:

• Breast feeding females.

• Pregnant women.

• Infectious diseases HIV, HBV, HCV

• Documented immunodeficiency

• Documented autoimmune disease

• Any serious or uncontrolled medical or psychiatric conditions, for example, severe pulmonary, cardiac or other systemic disease.

• Patient inability to participate as determined by PI discretion.

Related Conditions & MeSH terms

• Glioblastoma

Intervention

Biological:
• Personalized cellular vaccine
Biological: DC-based cellular vaccine. Subjects will undergo surgical resection and standard 6-week chemo/radiotherapy and cycles of TMZ treatment. They will receive biweekly cellular vaccines.

Locations

Country	Name	City	State
China	Guangdong 999 Brain Hospital	Guangzhou	Guangdong

Sponsors (4)

Lead Sponsor	Collaborator
Guangdong 999 Brain Hospital	Beijing Tricision Biotherapeutics Inc, Jinan University Guangzhou, Trinomab Biotech Co., Ltd.

Country where clinical trial is conducted

China, 

References & Publications (1)

Wang QT, Nie Y, Sun SN, Lin T, Han RJ, Jiang J, Li Z, Li JQ, Xiao YP, Fan YY, Yuan XH, Zhang H, Zhao BB, Zeng M, Li SY, Liao HX, Zhang J, He YW. Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients. Cancer Immunol Imm — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of treatment-emergent adverse events and severe adverse events [safety and Tolerability]	Incidence of adverse events and severe adverse events to measure safety and tolerability of mRNA-TAA pulsed autologous DC cellular vaccine	3 years since the beginning of the first vaccine
Secondary	Antitumor antigen specific T cell response	The frequency of peripheral CD8+ and CD4+ T cell response to the vaccine.	4 weeks after the last vaccine
Secondary	Progression-free survival	Progression-free survival will be monitored for 1year.	12 months since the beginning of the first vaccine.
Secondary	Overall survival	Overall survival will be monitored for 3 years.	3 years since the beginning of the first vaccine

External Links

•   Publication of the trial results